Siziopikou said, “When concurrent IHC results are negative (0 or 1+), it is recommended that the specimen be considered HER2 negative.” Clinical question 5 probed the diagnosis for cases with an average HER2 signals per tumor cell of ≥4 and <6 and the HER2/ CEP17 ratio of <2,...
The path followed by a case of HER2-negative HR-positive breast cancer from the moment of diagnosis to the present time: clinical caseIovanovici, LauraOncolog-Hematolog
Here, we developed and validated a new prognostic model for predicting the risk of distant metastasis in patients with pN0-N1, hormone receptor-positive, HER2-negative (HR+/ HER2−) breast cancer treated with hormone therapy alone. RNA was extracted from formalin- fixed, paraffin-embedded ...
stratified by disease category (early stage or locally advanced) and hormone receptor status; however, a slightly higher proportion of patients in the pertuzumab arm had clinical lymph node-negative disease and primary tumor stage T2, which may have impacted the tpCR and EFS/DFS rates. The rates...
Patients enrolled in the CALGB 40601 trial were significantly younger, more likely to be premenopausal, and at a more advanced clinical stage at diagnosis than those enrolled in the nonchemotherapy PAMELA trial. There were no significant differences between the trials in the hormone receptor status ...
Patients were stratified at randomization based on 3 factors, including tumor progression to metastatic phase in 2 or fewer years or more than 2 years after primary diagnosis, centrally determined estrogen receptor and progesterone receptor status (≥1 positive or both negative), and type of taxane...
Raghav KPS, Overman MJ, Yu R, Meric-Bernstam F, Menter D, Kee BK, et al. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. J Clin Oncol. 2016;34(15_suppl):3517. ...
Overall, specific, relapse-free, and distant metastasis-free survivals were similar among STARD3 positive and negative groups, independently of other prognosis factors. Conclusion: NST is an opportunity for HER2-positive cancers. In this series of over a hundred HER2-positive and non-metastatic ...
these patients had a PFS comparable to patients with HER2-positive disease at the outset. These results illustrate that re-biopsies could be considered on the development of disease relapse or progression in HER2-negative tumours, as it could dictate eligibility for HER2-targeted therapies. Conversely...
Staurosporin was used as positive control, whereas an isotype control antibody was used as negative control. FIG. 10: HER2×HER2 bispecific molecules induced downmodulation of HER2 receptor. Relative percentage of HER2 expression levels in AU565 cell lysates after 3 days incubation with 10 μg/mL...